Abstract
Bone metastasis of a malignant tumor causes various skeletal related events (SREs) and often harms patients' QOL. Bisphosphonates is a standard treatment medicine for the patient with bone metastasis of a malignant tumor. It is possible that Bisphosphonates improve and also maintain their QOL because it restrains manifestation of SREs. Particularly zoledronic acid is recommended for bone metastasis of all malignant tumors in a guideline of American Society of Clinical Oncology (ASCO). Bisphosphonates should be used positively for profit of the patient.
MeSH terms
-
Bone Neoplasms / complications
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / secondary*
-
Bone Resorption
-
Carrier Proteins / physiology
-
Clinical Trials as Topic
-
Cytokines / physiology
-
Diphosphonates / adverse effects
-
Diphosphonates / therapeutic use*
-
Evidence-Based Medicine
-
Humans
-
Imidazoles / therapeutic use
-
Membrane Glycoproteins / physiology
-
Osteoclasts
-
Pain / drug therapy
-
Pain / etiology
-
Quality of Life
-
RANK Ligand
-
Receptor Activator of Nuclear Factor-kappa B
-
Zoledronic Acid
Substances
-
Carrier Proteins
-
Cytokines
-
Diphosphonates
-
Imidazoles
-
Membrane Glycoproteins
-
RANK Ligand
-
Receptor Activator of Nuclear Factor-kappa B
-
TNFRSF11A protein, human
-
TNFSF11 protein, human
-
Zoledronic Acid